(Q34976738)

5 August 2017

1 reference

title

Cardiovascular toxicities of immunosuppressive agents (English)

1 reference

5 August 2017

1 reference

Leslie W Miller

1

1 reference

PubMed ID

12392286

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Transplantation

5 August 2017

1 reference

5 August 2017

2

1 reference

5 August 2017

807-818

1 reference

5 August 2017

9

1 reference

Mechanisms and consequences of arterial hypertension after renal transplantation

5 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Hyperlipidemia and cardiovascular disease after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Graft function and other risk factors as predictors of cardiovascular disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

24th Bethesda conference: Cardiac transplantation. Task Force 5: Complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Heart transplantation--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Sympathetic neural mechanisms of cyclosporine-induced hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Cyclosporine-induced hypertension in cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Immunosuppressants: tools to investigate the physiological role of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Effects of FK506 in rat and human resistance arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Hyperlipidemia in solid organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

FK 506: effects on glomerular hemodynamics and on mesangial cells in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Effect of alternate-day prednisone on plasma lipids in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

The adverse impact of cyclosporine on serum lipids in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Treatment of hyperlipidemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Rhabdomyolysis due to cerivastatin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Cardiac allograft vasculopathy: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

The renin-angiotensin system and fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Epidemiology of cardiovascular disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Hypertension after cardiac transplantation: pathophysiology and management.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Modulation of nitric oxide improves cyclosporin A-induced hypertension in rats and primates

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Hyperlipidemia in renal transplant recipients: natural history and response to treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Lipoprotein-apolipoprotein changes in renal transplant recipients: a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Determinants of lipid profile in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Effects of cyclosporine therapy on plasma lipoprotein levels.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Cyclosporine, low-density lipoprotein, and cholesterol

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Hyperlipidemia after renal transplantation: treatment with gemfibrozil

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Some Characteristics of Steroid Diabetes: A Study in Renal-Transplant Recipients Receiving High-Dose Corticosteroid Therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Morphological and functional changes of islets of Langerhans in FK506-treated rats

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Role of compensatory enlargement and shrinkage in transplant coronary artery disease. Serial intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Effect of cyclosporin A on rat smooth-muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Rapamycin's effect on vasomotion in the rat

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Endothelial dysfunction in coronary artery disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Effects of rapamycin in experimental organ allografting

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Evaluation of cyclosporine, mycophenolate mofetil, and Brequinar sodium combination therapy on hamster-to-rat cardiac xenotransplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Impact of cytomegalovirus infection on organ transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20902.X

7 January 2021

10.1034/J.1600-6143.2002.20902.X

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12392286